When do you consider altering treatment for a patient with metastatic osteosarcoma who showed poor response to upfront therapy with MAP (doxorubicin, cisplatin, methotrexate) chemotherapy?

What specific pathology results (ie tumor necrosis, surgical resection) and toxicity considerations play into this decision?